Plain-English translation of NCT06346600 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a follow-up study for people who already received an injection of SKG0106 in an earlier clinical trial for wet age-related macular degeneration (a serious eye condition affecting central vision). Researchers will monitor your eye health for up to 5 years after your injection to make sure the treatment remains safe and continues to work well. No new medication will be given during this study—you'll simply come in for regular check-ups and eye exams.
Wet age-related macular degeneration is a leading cause of vision loss in older adults, and new treatments like this medication offer hope for better outcomes. This long-term follow-up study helps doctors understand how safe and effective this treatment is over many years, which is critical information for deciding whether to offer it to more patients.
You likely qualify if…
You likely don't qualify if…
Since you already received the experimental injection in a previous trial, this study simply tracks how you're doing over time. You'll attend regular follow-up visits (typically at a medical center) where doctors will perform eye exams and safety assessments to monitor your vision and check for any side effects. The study lasts up to 5 years, and no new medication will be injected during this time—it's purely a monitoring study to understand the long-term results of your earlier treatment.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
China